Mood Disorders - Brown University



Mood Disorders

What Is A Mood?

Mood is the sustained tone of feeling that prevails over time for a patient. A normal mood is defined as euthymia (literally “feeling normal”). However, euthymia can be disturbed if a patient feels a prevailing and generalized sense of anxiety, panic, terror, sadness, depression, anger, rage, euphoria, or guilt. At times, the patient will describe this mood. Otherwise, the clinician must inquire or use cues from the mental status exam to infer the patient’s mood by evaluating affect. Affect is generally defined as the observable manifestations of emotion, whereas mood refers to the subjective experience of emotion. Particular attention should also be given to the quality of mood, noting its depth, length of time it prevails, and the degree of fluctuation.

What Is A Mood Disorder?

A mood disorder refers to a sustained abnormality of a person’s mood. Most often, the abnormal mood can be thought of in levels: when the mood is too high, a person is manic and when the mood is too low a person is depressed. Mood disorders can also cause both physical changes as well as changes in the process and content of thought. One must be careful to distinguish transient deviations from euthymia and actual mood disorders. Most people experience highs and lows but maintain a general balance of mood; it is only when these highs and lows persist for certain durations, meet a certain level of severity and meet the global criteria of causing dysfunction in a person’s life that they become mood disorders.

Depression

Phenomenology

“Feeling down, blah, blue, apathetic, sad, irritable, hopeless…depressed.” This is how a patient experiencing a major depressive episode might describe his or her mood. Depression is one of the most common psychiatric disorders worldwide. A major depressive episode consists of a period of at least 2 weeks during which the patient has experienced a depressed mood or anhedonia, which is the loss of interest in formerly pleasurable activities. In addition, a major depressive episode is characterized by suicidal ideation, changes in sleep and/or appetite, feelings of guilt, decreases in concentration, energy and/or psychomotor activity. In the United States, it is estimated that depression costs $43 billion due to treatments, loss of productivity and work missed. Depression is associated with approximately 80% of suicides. Clearly, a major depressive episode extends beyond simply “feeling blue.” It includes psychological and physical changes

which decrease a person’s ability to carry out and enjoy his or her life.

Despite the impairments caused by depression, not all patients will describe their depressed mood. A clinician can use the examination to identify patients who may be experiencing a major depressive episode. The depressed patient may present to the doctor with signs of poor self care. During the interview, the depressed patient may show psychomotor changes which can range from agitation, such as fidgeting, to retardation, such as slow, soft, monotonous speech or lack of speech. The depressed patient may have experienced significant gain or loss of weight due to appetite changes. Patients with major depression may perform poorly on the mental status exam due to their decreased ability to concentrate, process information and/or due to a lack of effort. Older and younger patients will often complain of physical ailments or irritability. Patients who work or go to school might report a drop in their performance. Many depressed patients report decreased amounts of sleep, however, others patients may sleep too much. The majority of depressed patients experience both a decrease in their energy level and a lack of motivation. Some patients will express a sense of hopelessness, the feeling that life is not worth living. When working with a depressed patient, it is important to inquire regarding any suicidal intentions, including the intensity and lethality of these thoughts. Once major depression disorder is identified, the clinician has a range of effective methods to treat this disorder.

Epidemiology

The Epidemiologic Catchment Area (ECA) study reports the following statistics on depression:

• 5% lifetime prevalence of depression

• 2:1 female to male ratio

• socioeconomic factors not clear

The National Comorbidity Study reported:

• 17% lifetime prevalence

• 12% male, 21% female

This study attributed its higher lifetime prevalence to more comprehensive questions. Of note, only people under 55 were surveyed. They proposed that their questions increased recall of major depressive episodes which may not otherwise have been easily remembered.

Etiology

The limbic system has been identified as playing a central role in the mediation of emotional processes. Thus, dysfunction of this system contributes to the etiology of depression. The limbic system consists of a number of highly interconnected structures that function to integrate internal and external inputs relevant to the coordination of major neurobehavioral processes (emotional, cognitive, vegetative, autonomic, and motor). The maintenance of euthymia depends on the interactions of a widely distributed network of cortical-limbic and cortical-striatal pathways.

It is possible to organize limbic and other related brain structures on a regional basis that also reflects discrete neurobehavioral functions:

• Dorsal Compartment

Functions subserved by the dorsal compartment are attentional, cognitive, and psychomotor in nature. The dorsal compartment consists of the dorsolateral prefrontal cortex, the dorsal anterior cingulate, the inferior parietal cortex, and the striatum (including the caudate, the putamen, and the nucleus accumbens). Some authorities would also include the mediodorsal thalamus in this compartment.

• Ventral Compartment

Functions subserved by the ventral compartment are vegetative, autonomic, and somatic in nature. This consists of the hypothalamus (including the hypothalamic-pitituary-adrenal [HPA] and hypothalamic-pitituary-thyroid [HPT] axes), the insula, the subgenual cingulate, the hippocampus, and the brainstem (including the midbrain and pons). Some authorities would include in this grouping the anterior thalamus.

• Rostral Compartment

This compartment is responsible for the subjective experience and understanding of internal mood states as well as the facilitation of interactions between the dorsal and ventral compartments. This compartment consists of the rostral anterior cingulate.

• Indeterminate compartment

Responsible for mediating several more elemental emotional states, such as fear and anxiety. This compartment is comprised of the amygdala.

Clinically significant depressive syndromes consist of abnormalities in emotional, cognitive, vegetative, autonomic, and motor functions. Based on a recognition of these clinical features, the compartmental approach articulated above can be used to formulate hypotheses about the neuroanatomy of depressive illness. Specifically, we can speculate that:

• sadness and depression are associated with functional decreases in dorsal limbic (anterior and posterior cingulate) and neocortical (prefrontal, premotor, and parietal) regions, causing decreases in attention and cognition and the psychomotor retardation seen in depressed patients.

• depression can be associated with functional increases in ventral paralimbic (subgenual cingulate, anterior insula, hypothalamus, and caudate) regions, which increases the vegetative, autonomic and somatic functions of this compartment.

Extrapolating from this, it is reasonable to hypothesize that effective treatment for depression must involve (a) the disinhibition of underactive dorsal regions and (b) the inhibition of the overactive ventral regions. It is important to note that this disinhibition of the dorsal regions may result from the therapeutic inhibition of the ventral regions.

Depression And Neurotransmitters

However, categorizing the dorsal and ventral compartment activities in depressed patients does not answer the fundamental question of what is causing this imbalance in activity. Most research on depression is currently focused on the role of neurotransmitters. Neurotransmitters can affect mood by binding at a postsynaptic receptor, resulting in a process of transduction, amplification and activation of an effector mechanism. Their ultimate consequence is some biological or behavioral response. Depression is known to be tied to levels of specific neurotransmitters. For example, depression can be induced by reserpine treatment, which depletes serotonin. In addition, most currently accepted antidepressant drugs act to increase monoamine neurotransmitter function in the brain. In the mid-1960's, investigators in the United States hypothesized that depression was characterized by a deficit of norepinephrine (NE) function. At about the same time, investigators in the United Kingdom posited a similar role for serotonin (5-hydroxytryptamine, 5-HT). Over the past 35 years, the great preponderance of neurochemical research in depression has focused on these two neurotransmitters. The catecholamine hypothesis of mood regulations suggests that there is a decrease in the catecholamines in depression and an increase in mania. While it has not been possible to directly measure concentrations of these neurochemicals in the brains of depressed patients, many studies have measured decreased norepinephrine and serotonin metabolite concentrations in urine, plasma, and cerebrospinal fluid. There is also some evidence that pre-treatment levels of norepinephrine metabolites may predict response to medication. Moreover, animal models have also proven useful in identifying changes in these neurotransmitters associated with specific behavioral states. What is clear is that many of the symptoms associated with depression appear to be mediated by serotonin (e.g., poor impulse control, diminished sex drive, decreased appetite, irritability) and norepinephrine (poor attention and memory, diminished concentration, decreased socialization, altered states of arousal).

Other neurotransmitter systems have also been implicated in the pathogenesis of depression. For example, dopamine (DA) appears to be critically involved in the mediation of reward and arousal, and both of these functions are severely compromised in depression. Indeed, some drugs which increase dopamine function (e.g., cocaine and amphetamine) are well known to have elevating (euphorigenic) effects on mood, although these drugs are generally not effective in treating clinical depression. Excessive acetylcholine (Ach) activity has also been associated with depressive symptoms, but anticholinergic drugs have little beneficial effect on mood (acetylcholine appears to be more centrally involved in the maintenance of normal memory processing). Gamma aminobutyric acid (GABA) is one of the most common neurotransmitters, and decreased plasma levels of GABA have been demonstrated in some depressed patients; in general, however, drugs which act to promote GABA function appear to have more beneficial effects on anxiety than on depression.

While an imbalance of neurotransmitter functions clearly plays a role in the etiology of depression, the original deficit theories have not been confirmed. In fact, a good deal of evidence suggests that the story goes way beyond neurotransmitters. The receptor hypothesis suggests that a defect in the regulation of receptors for neurotransmitters causes depression. This hypothesis is supported by evidence that medications for depression and mania induce changes in pre- and post-synaptic density of receptors. Although antidepressants quickly increase synaptic neurotransmitter levels, the lag time of up to 6 weeks before the drug’s full effects take hold also suggests the drugs work via regulation at the receptor level, not at the neurotransmitter level. The post-receptor hypothesis implicates changes in second messenger systems in the etiology and pharmacological treatment of mood disorders. Antidepressant treatments have been shown to modify activity of the G-protein and cyclic adenosine monophosphate (cAMP) signal transduction cascades. Because certain alleles of G-proteins have been shown to correlate with responsiveness to antidepressants, antidepressants are hypothesized to work by modifying G-protein activity. Many antidepressants stimulate the cAMP cascade, which is located downstream of the G-protein. This results in increased production of brain-derived neurotrophic factor (BDNF), which exerts a trophic effect upon cholinergic and dopaminergic neurons.

Depression And Neuropeptides

Changes in the function of specific neuroendocrine systems also have been consistently associated with depression. The largest body of literature documents abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis, which includes corticotropin-releasing hormone (CRH) and glucocorticoids (specifically cortisol, the “stress hormone” which mediates metabolic and immune function). Numerous studies have demonstrated that depressed patients have elevated CRH and free cortisol levels. The dexamethasone suppression test (DST) introduces an exogenous source of glucocorticoids into the body and tests the regulation of cortisol levels. In normal physiology, the excess glucocorticoids work via negative feedback to reduce the level of CRH and thus lower cortisol output. However, many depressed patients maintain high CRH levels when given the DST. Stimulation of CRH receptors in the cerebral cortex, amygdala and locus coeruleus causes appetite suppression, sleep disturbances, behavioral problems and increased vegetative function, symptoms often evident in depressed patients. Interestingly, CRH is also under the regulation of various neurotransmitters (e.g., serotonin, norepinephrine, acetylcholine) which themselves have been implicated in depression.

Another large body of data has demonstrated abnormalities in the hypothalamic-pituitary- thyroid (HPT) axis, which includes thyrotrophin releasing hormone (TRH), thyroid stimulating hormone (TSH) and the thyroid hormones thyroxine (T4) and triiodothyronine (T3). Just as with CRF, several studies have demonstrated increased levels of TRH in the cerebrospinal fluid of depressed patients compared with age- and sex-matched healthy controls. The comorbidity between hypothyroidism and major depressive disorder provides another link between the HPT axis abnormalities and depression.

Other neuropeptides have also been implicated in depression. Numerous investigators have shown decreased levels of, and responsiveness to, growth hormone (GH). Some studies have demonstrated abnormal responsiveness to gonadotropins (e.g., estrogen, progesterone, and progesterone metabolites), particularly in women with premenstrual mood syndromes. A few studies have suggested abnormalities in the regulation of posterior pituitary hormones vasopressin and oxytocin in depression, as well as in the endogenous opioids (endorphins and enkephalins), although these findings are less consistent.

Depression And Genetic Factors

A familial basis for depression has been well established for about 40 years. The concordance of depression supports a genetic link:

• 30% in dizygotic twins

• 50% in monozygotic twins.

• Twin studies also suggest that the heritability of depression is similar to, or slightly greater than, the heritability for many other common medical conditions (e.g., adult-onset diabetes, hypertension).

• In general, an individual with a first-degree relative having depression is at approximately 3 times greater risk than the general population for developing depression him/herself.

To date, a specific gene predisposing to depression has not been identified, although the gene which codes for the serotonin transporter has been implicated in several studies. Recent research suggests that the inheritance of depression is likely to be polygenic (i.e., reflecting the inheritance of several genes), rather than reflecting an abnormality at a single major locus.

Depression And Experiential Factors

It has long been recognized that sustained or severe stress can precipitate depressive episodes. Stressors which entail diminished self-esteem or personal loss are particularly depressogenic. Extensive research has now shown that individuals vary in their susceptibility to such stressors, reflecting characteristics of the individual as well as characteristics of the stressor itself. Interestingly, the identification of a precipitating stressor is of relatively little value in determining whether or not a given patient with depression will respond to antidepressant medication.

Pathology

There is no single clear pathologic finding that correlates with clinical findings, but there are many associated findings that give hints to the etiology of depression.

• Depressed patients display alterations in circadian rhythms, often demonstrating early morning awakening, early fatigue during the day and more REM sleep early on.

• Changes in sleep EEGs, including decreased total sleep and decreased REM and stage 4 sleep.

• Strokes in certain areas of the brain such as lesions in the dominant frontal or basal ganglia areas have been shown to predispose to depression

• As already noted, depressed patients do not show normal feedback of HPA axis with the dexamethasone suppression test.

• Functional imaging in depressed patients shows hypometabolism in certain areas, especially in the prefrontal areas (orbital cortex, basal ganglia).

• Volume reductions in the prefrontal cortex and hippocampus occur in depressed patients.

• Reductions in neuronal and glial cells in the dorsolateral and orbital prefrontal cortex, especially in the areas that receive the greatest amount of monoamine input.

Diagnoses And Criteria (DSM-IV)

Episodes versus disorders: Episodes should not be equated with disorders, but rather comprise clusters of symptoms that will be used in defining the actual disorders.

The Episode

The Disorder

[pic]

Important Differential Diagnoses

• Adjustment Disorders

Adjustment disorders cover the concept of a response to a psychosocial/environmental stress. This disorder usually manifests as some emotional symptoms, but these do not cover the full spectrum of a mood disorder. If the response to the stressor meets criteria for another psychiatric disorder (like major depression or bipolar disorder), then one would diagnose that disorder instead of adjustment disorder.

• Bereavement (Grief)

Similar rationale to the Adjustment Disorders.

• Dysthymia

This is a chronic depressed mood lasting 2 years in adults the symptoms of which fall short of the DSM definition of a major depressive episode.

• Bipolar Disorder

Absence of a manic or hypomanic episode differentiates major depressive disorder from the bipolar disorders.

• Anxiety disorders

Anxiety can share symptoms with depression, such as racing thoughts, sleep disturbance and irritability. Anxiety itself can actually be a symptom of depression. The primary difference is the prominence of the moods of dysphoria and anhedonia in depression. Anxiety and depression are commonly comorbid, however, so both may occur.

• Psychotic disorders

Schizoaffective disorder shares features of both schizophrenia and mood disorders. Schizoaffective patients have persistent psychotic symptoms with intermittent periods of mood symptoms. Although psychotic symptoms can occur in depressed patients, these symptoms are usually congruent with a depressed mood, i.e. hearing voices saying you are a failure. In major depressive disorder, once the depressed mood has lifted, patients will no longer experience these psychotic symptoms. However, with psychotic disorders, the patient will still experience psychotic symptoms even when they are not depressed or manic.

• Substance Abuse disorders

Many substances can cause depressive symptoms either through use or as a result of withdrawal. However, depression should cease after 3-4 weeks of alcohol abstinence and 1 week after stimulant abstinence. Substance abuse disorders and depression are commonly comorbid.

• Personality disorders

Some patients with personality disorders frequently show depressive symptoms, especially patients with type B personality disorders such as borderline personality. The difference between a patient with major depressive disorder and a patient with a personality disorder is in the timing of depressive symptoms--major depressive episodes are stable over the course of days to weeks, whereas mood lability as a part of a personality disorder tends to vary rapidly throughout the day. There is a high incidence of comorbidity between depressive disorders and personality disorders.

• Mood Disorder Due to a General Medical Condition

In this condition, the mood disorder is judged to be directly related to the medical condition (not just a "reaction" to a disorder). Many medical illnesses can mimic mood disorders. It must be emphasized that diagnosis of a secondary mood disorders implies direct causation of a mood disorder by a physical phenomenon. For example, cerebrovascular accidents, particularly those occurring in the dominant fronto-parietal area, can cause the onset of depression. Quite often medical disorders feature one or more depressive symptoms, but generally not enough to meet criteria for a major mood disorder. Some medical illnesses in which depression-like symptoms are evident include:

o Cancer: Adenocarcinoma of the pancreas can present with depression-type symptoms such as fatigue and poor appetite.

o Dementias: Can present with social withdrawal and emotional distress that may be misperceived as a mood problem.

o Parkinson's Disease: Associated bradykinesia can be misinterpreted as the psychomotor retardation of depression.

o Obsessive-Compulsive Disorder: Some suggest that OCD is better included as a mood disorder.

o Multiple Sclerosis: Patients display emotional lability as part of a pseudobulbar palsy. This can be misinterpreted as depression, but tends to be transient and to lack much emotional content.

o Hypothyroidism: Can cause a depression-like condition that is unlikely to resolve unless the primary disorder is corrected.

o Adrenal problems: Have been associated with both depressive- and manic-like conditions, for example Cushing's syndrome.

• Substance-induced disorders

In addition to the substance use disorders mentioned above, a wide variety of substances have been listed as having effects on mood. Some had been implicated in causing "true" mood disorders (ex. Reserpine causing depression). More often, they cause some symptoms associated with depression. Diagnosis of substance induced mood disorders can only be made when mood symptoms are directly due to the substance, are in excess of what would be expected for that substance, and are bad enough to warrant independent attention. To treat substance-induced disorders, try to remove the offending substance. In some cases, this cannot be done (i.e. a patient requiring high dose steroids). In that case, treatment with an antidepressant may help.

Comorbid Disorders

• Anxiety

Twin studies suggest a common genetic origin between anxiety and depression, with the differentiation of the two disorders determined by environmental factors. Anxiety is so frequently comorbid with depression that some question whether the two can really be considered distinct disorders at all. An example is panic disorder. As many as 50% of patients with panic disorder have comorbid depression. The presence of mixed anxiety and depression may predict a poorer prognosis and response to treatment.

• Dysthymia

The concurrent presence of both dysthymia and major depressive disorder is called double depression. By definition, dysthymia and major depression can only be recognized as coexistent if the dysthymia precedes the episode of major depression, or if there has been remission from major depression for at least two months. In double depression, the episodes of major depression appear to be superimposed upon a more chronic depression. Studies suggest that a person with double depression recovers more easily from a major depressive episode than a person with major depression alone. However, recovery is not to a state of euthymia and relapse is more likely.

Substance Abuse

The ECA study found that about 13% of those with substance abuse or dependence also have a lifetime diagnosis of a mood disorder. Similar results have been found in other countries. Alcoholism predicts a worse outcome for a mood disorder. When compared with non-alcoholics, alcoholics may be half as likely to recover from an episode of major depression after even 10 years. Some theories regarding the relationship between mood disorders and alcoholism include the self-medication medication, alcoholism as a forme fruste, and the idea of secondary mood disorders.

Other substance use disorders include nicotine dependence, cocaine and opioids. There is a high prevalence of depression in smokers, and this may negatively influence attempts to quit.

• Psychotic Disorders

It is difficult to judge comorbidity, as one can have psychotic depression, and an understanding of the longitudinal course is usually needed to differentiate the two. Psychotic symptoms that mirror the course of a mood disorder are likely secondary to the mood disorder, whereas symptoms that predate or outlast mood symptoms are more likely to be a comorbid disorder: Schizophrenic patients can often have comorbid mood symptoms. By definition, schizoaffective disorder includes mood symptoms, however both the mood and psychotic symptoms would be accounted for in that single diagnosis. The presence of psychotic features, whether as a symptoms of the mood disorder, or independently of it, has an adverse affect on the prognosis for the mood disorder.

• Depression in the Medically Ill

Depression is common in medical patients. 2-4 percent of medical patients in the community, 5-10 percent of primary care patients, and 10-14 percent of medical inpatients are depressed. It is often unrecognized and untreated in the medical population. Such inadequate treatment may in part reflect the obsolete view that depressive symptoms triggered by medical illness are not the same as "clinical depression." Comorbid medical illnesses predispose an individual to a worse course of major depression.

• Personality Disorders

There are high rates of comorbidity between personality disorders and major depression, with a range from 30% to almost 90%. Inpatient samples typically see comorbidity in the dramatic types of personality disorders (cluster B: histrionic, narcissistic, borderline, and antisocial) because the impulsive behaviors associated with these personality disorders are likely to lead to hospitalization. Outpatient samples are more likely to show anxious/fearful types of personality disorders (cluster C). It is generally believed that depressed patients with a comorbid personality disorder are less likely to respond to somatic treatments. Few controlled studies have tested this belief; naturalistic studies, however, tend to support this assumption. This poorer response to treatment may, in part, reflect a greater severity of illness that results from the combination of major depression and a personality disorder. Some studies also suggest that depressed patients with borderline personality features may preferentially respond to monoamine oxidase inhibitors. A number of investigators have reported a relationship between comorbid borderline personality disorder, depression, and increased risk of suicide.

Course and Prognosis

The first major depressive episode typically occurs in the mid-20’s, although there is a wide distribution ranging from childhood to old age. Depression has usually been characterized as a self-limited disease, with an average duration of six to nine months. Newer studies suggest, however, that a significant number of patients recover more slowly or do not ever fully recover. The greatest probability of recovery was early in the course of the illness, while chances of recovery diminish greatly if the patient hadn't yet recovered in the 1st year.

A number of studies suggest that depression, for many, may be a lifetime illness. Significant numbers of patients experience multiple episodes of depression. Others never fully recover from their illness, but may stabilize at a level of dysthymia or sub-syndromal depression. The risk of relapse for depressed patients is high. At least 60% of patients with a single major depressive disorder will have a second episode, 70% of individuals with 2 episodes will have a third, and 90% of individuals who have had three episodes will have a fourth. Comorbid disorders can modify the course of major depression disorder. Up to 15% of depressed patients die from suicide.

Predictors of poor recovery/relapse included:

• Long duration of illness

• Married status

• Inpatient hospital status at the time of intake

• Low family income

• Presence of other psychiatric disorders

Treatment

Antidepressant classes include tricyclics, monoamine oxidase inhibitors (“First Generation Antidepressants”), serotonin reuptake inhibitors and bupropion (“Second Generation Antidepressants”) and others (“Third Generation Antidepressants”). Overall, there is a 70-80% response rate to these drugs when used to treat major depression. They are also used for treatment of anxiety disorders and other disorders. When considering pharmacological treatment, it is important to consider the following clinical principles: target symptoms, response time to medications, the option of psychotherapy. Side effects and risks must also be considered, including the predictable effects, drug interactions, idiosyncratic effects, and allergic reactions. A full response to antidepressants can take up to 6 weeks, although an initial response is commonly observable in approximately 2 weeks. Due to receptor interaction, antidepressants can have anticholinergic effects, adrenergic effects and serotonergic effects.

• Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs are the first line treatment for depression. SSRIs inhibit serotonin reuptake, which is the primary mechanism of serotonin termination. The main advantage may lie in reduced side effects compared to classical tricyclics. Fluoxetine (Prozac) is an example of an SSRI.

Side effects

SSRIs can cause nausea, vomiting, headache and sexual dysfunction for both males and females.

• Tricyclic Antidepressants (TCAs)

Tricyclics inhibit biogenic amine reuptake, and, depending on their structure, can be good inhibitors of NE and/or 5-HT reuptake. Most are not good inhibitors of DA reuptake. Secondary amines (desipramine) are more effective for NE neurons. Tertiary amines (amitriptyline) are more effective for 5-HT neurons. This is consistent with theories of amine function and mood, although these compounds do not cause mood elevation in non-depressed subjects

Side effects

Tricyclic antidepressants can produce antimuscarinic effects (dry mouth, constipation, visual effects, sedation, drowsiness), α1 blockade resulting in postural hypotension and can produce a switch to mania in bipolar patients.

• MAO inhibitors

The mitochondrial enzyme Monoamine Oxidase (MAO) degrades catecholamines. MAO inhibitors decrease the degradation of NE, 5-HT and DA to prolong their action. MAO inhibitors are used when tricyclics and/or SSRIs are ineffective. The drugs phenelzine and tranycypromine are examples of MAO inhibitors.

Side effects

MAO inhibitors can cause a hypertensive crisis, especially when one consumes foods with excess tyramine such as wine and cheese (hence “the wine and cheese effect” of MAO inhibitors). This is because tyramine, a metabolite of tyrosine, increases blood pressure. Usually tyramine is broken down by MAO, but this degradation does not occur with use of MAO inhibitors.

• Newer Antidepressants

The original first generation antidepressants were discovered serendipitously. Subsequent first generation antidepressants were attempts to copy the effects of these first agents. This group includes the TCAs and MAOIs. Second generation agents were an attempt to isolate the likely therapeutic effects of antidepressants—hence make them more “selective.” These include the SSRIs. Unfortunately, this group turned out to be no more effective than the first group, although they were more tolerable (which can be of great practical significance). The next, or Third Generation, have largely been an attempt to combine effects in the hope of producing a more effective antidepressant. Examples of third generation antidepressants are the combination Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) venlafaxine and duloxetine. Nefazodone, another third generation agent, combines both serotonin and norepinephrine transporter inhibition with antagonism of the 5-HT2A and α∀1-receptors. Mirtazapine, a Mixed Serotonin/Noradrenaline Antagonist appears to have a direct effect on receptor sites, blocking both the noradrenergic ∀2-autoreceptors as well as antagonizing 5-HT2 and 5-HT3 receptors, the latter effect which may help concentrate the action of serotonin on the therapeutically important 5-HT1A receptors.

• ECT

First used in the 1930s for schizophrenia, this was found to be more effective for depression. It is used in conjunction with a muscle relaxant to avoid fractures. The mechanism by which ECT works is not known. It has been suggested that down regulation of β receptors in the CNS is a common feature of most antidepressant treatments. It has also been suggest that down regulation of α2 presynaptic receptors occurs, which would increase NE release receptor (or other protein) alterations, and would fit better with the time dependency for clinical effect. ECT is used for refractory, life-threatening depression.

• Psychotherapy

Cognitive-Behavioral Therapy (CBT) is based on learning theory. Learning theory suggests that behaviors are learned (i.e., made more likely to occur), usually through some sort of reinforcement. CBT applies learning theory to depression by suggesting that thoughts can also be learned, and that we learn to think a certain way and develop automatic thoughts and responses to situations. Depressive ways of thinking can become habitual. However, what we learn can be unlearned through practice, hence the rationale for CBT. CBT is an active therapy with lots of homework and assignments. Interpersonal Therapy (IPT) is based on the notion that depression is a response to loss or perceived loss in social network. It is also very active and practice based. Other psychotherapies shown to be effective include Psychodynamic Therapy and Marital/Family Therapy.

When To Choose Meds Versus Psychotherapy?

The weight of data supports the following conclusions:

• Medication is superior to therapy for severe depression.

• Medication and therapy are probably equal for mild to moderate depression.

• Combination of medication and therapy likely confer an advantage over either alone, perhaps a strong advantage.

• Psychotherapy may confer some protection against episodes, even after the therapy is over.

Antidepressants: Special Populations And Concerns:

Children And Adolescents

Much concern has been raised over the use of antidepressants after the U.S. Food and Drug Administration (FDA) raised concerns over a possible link between antidepressants and suicide in children and adolescents. As of October 2004, the FDA began requiring manufacturers of antidepressants to include a black box warning that the medications "increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents with major depressive disorder (MDD) or other psychiatric disorders." The basis of this warning was a pooled analysis of 24 short-term (4 to 16 weeks) placebo-controlled trials involving over 4,400 patients. The studies included a variety of antidepressants (mostly SSRIs) and childhood disorders (mostly depression). The analysis found an increased risk (4%) of suicidal thinking or behavior compared with placebo (2%). It should be noted that this increased risk remains low compared to the risk of suicide in patients with depression, and that no actual suicides occurred in any of the trials.

The warning has generated a good deal of controversy, given the nature of the analysis, the high rate of depression in children and adolescents, and the fear that depression will not be appropriately treated in light of this warning. The American Academy of Child and Adolescent Psychiatry currently opposes the black box warning. They recommend continuing to use antidepressants, including SSRIs, for childhood and adolescent depression, along with appropriate education of the family regarding suicidal risk, and signs of behavioral toxicity, and appropriate patient monitoring (their full recommendations are available on their web site at ).

Pregnant And Postpartum Patients

The commonly used antidepressants show no compelling evidence of teratogenicity, however definitive data are lacking. SSRIs are most commonly used in pregnancy, largely for reasons of tolerability. Fluoxetine has been reported to have low teratogenicity in pregnancy, however the data are limited to open, uncontrolled reports (Pastuszak et al, 1993). All antidepressants are secreted in breast milk, and though there are isolated reports of adverse behavioral effects associated with antidepressants systematic investigations are lacking.

Geriatric Patients

Elderly patients have a decreased muscle to fat ratio and have decreased efficiency of the hepatic microoxidase system. The result of both effects is that antidepressants can have increased plasma levels and half-lives in the elderly, which can exacerbate the side effects from antidepressants in elderly patients versus younger patients. We therefore hear the oft repeated adage to “start low and go slow” in elderly patients. Though this is prudent, many elderly patients have normal metabolisms and will require normal doses of antidepressants. There is support for the efficacy of virtually all antidepressants in the elderly depressed patient, though the majority of data is in the healthy elderly.

Suicidal Patients.

Similar to the discussion of child and adolescent data, there remains a concern in adults that antidepressants may raise the risk of suicide. Metanalyses (Mann and Kapur, 1991; Kapur et al, 1992) and one prospective study (Leon et al, 1999) suggest that if any pro-suicide effect exists, it is extremely rare, and not unique to any one antidepressant. At least one study suggests that fluoxetine may have a protective effect in some suicidal patients (Sachetti et al, 1991). Though some concerns about potentiating suicidal behavior may remain, these should be balanced over the clear risk of suicide in patients with untreated depression. As many suicidal patients choose to overdose on their medication, in patients considered at high risk for suicide, antidepressants with wide safety margins should be chosen. For this reason, tricyclic antidepressants are often avoided: doses of only 3-5 times the therapeutic dose can be lethal in adults (and the ratio is lower in children: doses of 5 mg/kg can be toxic). Most of the second and third generation agents are relatively safe in overdose, though bupropion can cause seizures in about 1/3 of overdoses.

|Table 1. Commonly used drugs for treating depression |

| |Class |t½ |Metabolism |Side Effects |

|Fluoxetine (Prozac, others) |Selective Serotonin |2-3 days (+ active |95% protein bound, liver |nausea, vomiting, diarrhea, anorexia |

| |Reuptake inhibitors |metabolite, 7-10 |met.: P-450 2D6 | |

| |(SSRI) |days) |inhibition | |

|Paroxetine (Paxil) | |@ 1 day | | |

|Sertraline (Zoloft) | | |95% protein bound, less | |

| | | |affinity for p-450 | |

| | | |inhibition. | |

|Citalopram (Celexa) | | | | |

|Fluvoxamine (Luvox) | |15 hours |80% protein bound, little| |

| | | |P-450 2D6 inhibition, but| |

| | | |does inhibit 1A2, 2C9, | |

| | | |3A4. | |

|Venlafaxine (Effexor) |Serotonin (5HT) and |5 hours |25% protein bound, |SSRI side effects, + increased BP. |

| |Norepinephrine (NE) | |inhibits P450 2 D6. | |

| |Reuptake inhibitor | | | |

|Duloxetine (Cymbalta) | |12 hours |>90% protein bound. |Anticholinergic and SSRI side effects |

| | | |Inhibits both P450 2D6 | |

| | | |and 1A2 | |

|Mirtazapine (Remeron) |?Antagonism of |20-40 hr |85% protein bound. |Sedation, weight gain, postural |

| |presynaptic | |Extensively metabolized |hypotension. |

| |receptors: increases | |in the liver; excreted in| |

| |5HT and NE | |both the urine (75%) and | |

| | | |feces (15%). | |

|Nefazodone (Serzone) |SSRI + 5HT2 |2-4 hours |99% protein bound, |Nausea, vomiting, sedation. |

| |postsynaptic blockade| |inhibits P-450 3A4 | |

|Trazodone | |6 hours |90% protein bound. |Sedation, postural hypotension |

|Bupropion (Wellbutrin) |dopamine agonism, ? |6-24 hours |80% protein bound |anxiety, agitation, insomnia. |

| |Norepinephrine | | | |

| |effect? | | | |

|Amitriptyline, Doxepin, |Tricyclic |15-20 hours |liver metabolized, high |sedation, anticholinergic effects, |

|imipramine, desipramine |antidepressants: | |individual variation |weight gain, orthostatic hypotension. |

| |inhibit reuptake of | | | |

| |norepinephrine, | | | |

|nortriptyline, maprotiline | |1-2 days | | |

|protriptyline | |3 days | | |

|phenelzine, tranycypromine | monoamine oxidase |3 hours |liver metabolism, lots of|orthostasis, dizziness, |

| |inhibition | |drug interactions |anticholinergic effects. |

| | | | |Tyramine-cheese reaction. |

Bipolar Disorder

Phenomenology

There are two recognized types of bipolar disorders: bipolar I disorder and bipolar II disorder. The diagnosis of bipolar I disorder is defined by a single manic episode lasting for at least a week (or less if hospitalization is required), but generally the course of the disorder involves a cycling between mania and depression. During manic episodes, patients experience a heightening of mood. Patients may feel a sense of euphoria and invincibility or they may experience dysphoria, irritability and delusions of persecution. Manic episodes affect more than mood; a manic episode is characterized by symptoms other than heightened mood including inflated self-esteem or grandiosity, decreased sleep requirement, flight of ideas, distractibility, increased activity level, psychomotor agitation and/or excessive involvement in pleasurable but risky activities.

A typical manic patient might appear well groomed, possibly displaying a dramatic change in appearance (e.g. a drastic change in wardrobe, make-up, or hairstyle). The manic patient will probably be very talkative and may initially appear more clever or entertaining; however, conversation will become tangential with puzzling jumps from one subject to another. Often a manic patient has an inflated sense of self-confidence and feels invincible. This often leads the patient to take on unrealizable projects, engage in risky sexual activities, spend too much money, and get in trouble with the law. After the manic episode has passed, the bipolar patient will often come to regret actions carried out during the manic episode. The majority of bipolar I disorder patients also cycle into major depressive episodes.

In bipolar disorder type II, the patient has experienced at least one major depressive episode and at least one hypomanic episode (see below for definition). The hypomania seen in bipolar disorder type II is of shorter duration and causes less impairment in the patient’s life than the mania seen in bipolar disorder type I. Hypomanic episodes may actually result in increased productivity due to the person’s increased energy level. This contrasts with mania where the individual is too disorganized to accomplish much, despite a greatly augmented energy level.

While a genetic component to bipolar disorder has been identified, little is understood about the etiology of the disease. Still, there are effective methods of mood stabilization that are used to treat both types of this disorder.

Epidemiology

• 0.4% to 1.6% lifetime prevalence of bipolar I disorder

• 1:1 male to female ratio

Adoption and twin studies show a strong genetic component. In some families, bipolar disorder type I linkage has been established to a locus on chromosome 18.

• 0.5% lifetime prevalence of bipolar II disorder

• More common in women than men

First-degree relatives of bipolar II disorder patients have higher rates of bipolar II disorder, bipolar I disorder and major depressive disorder, suggesting a genetic link between these disorders.

Etiology

The etiology of mania is unclear; however, disturbances in biogenic amines have been implicated. While norepinephrine metabolite levels are normal during mania, other neurotransmitters such as dopamine, acetylcholine and serotonin have all been implicated in manic and hypomanic episodes, as well as in the depressive symptoms that follow. The administration of alpha-methyltyrosine, which blockades DA synthesis, and/or antipsychotics, which block DA receptors can shorten the duration of a manic episode. L-DOPA administration can induce hypomania in patients. Physostigmine, which increases cholinergic activity in the brain, decreases mania. From data regarding dopamine and acetylcholine during manic episodes, it has been suggested that mania can result from DA overactivity relative to acetylcholine. Some studies have associated serotonin receptor polymorphisms with bipolar disorder and it is known that serotonin agonists used as anti-depressants can induce a switch to mania in bipolar patients.

Studies suggest that alterations in GABA receptor subunits and decreased GABA neuron density are involved in bipolar disorder. Increased glutamate activity may be associated with bipolar disorder, and antidepressants that increase glutamate receptor density can trigger a manic episode. Many of the anticonvulsants used to treat mania act to increase GABA and decrease glutamate functions.

Mania can be induced in predisposed patients in a variety of ways. As noted above, some drugs can trigger a manic episode, particularly antidepressants. Sleep deprivation has been known to cause mania. Light exposure, as with light therapy (for seasonal depression) has also been reported to trigger manic episodes. Several neurological injuries (see below) can also cause bipolar type symptoms.

The mechanism of depression in bipolar patients is presumably similar to the mechanism in major depressive disorder; however, this presumption has not been intensively studied. Some indirect data, particularly treatment studies, makes one wonder whether the depression in bipolar disorders is a different entity altogether.

Pathology

Some laboratory findings are abnormal in individuals with manic episodes versus normal individuals, although these are not diagnostic:

• Increased cortisol secretion

• Polysomnographic abnormalities

• Abnormalities in monoamine neurotransmitter systems

Diagnoses and Criteria (DSM-IV)

Episodes

Disorders:

Differential Diagnosis

• Mood disorder due to a General Medical Condition

Secondary mania is directly traceable to a medical condition. For example, mania has been associated with injury to limbic areas on the right side of the brain, stroke, tumors and multiple sclerosis.

• Substance Induced Mood Disorder

Stimulant drugs can also cause euphoric mood, pressured speech, irritability, agitation and delusions. Antidepressant therapy can induce mania directly in a patient with a history of only unipolar depression, and corticosteroids can induce secondary mania.

• Psychotic Disorders

Many psychotic disorders also share delusions, irritability and agitation. However, psychotic patients have psychotic symptoms independent of mood symptoms, whereas bipolar patients do not.

Comorbidity

• Personality disorders

While many bipolar patients have personality disorders, the diagnosis of personality disorder in the bipolar patient can be influenced by the patient's mood at the time and by other comorbid conditions. In addition, many of the symptoms of personality disorders, such as narcissism, anxiety and paranoia overlap with the symptoms of mania.

• Anxiety disorders

Studies have shown high comorbidity between bipolar disorder and anxiety disorders such as panic disorder, OCD, social phobia, and post-traumatic stress disorder.

• Substance Abuse

It is estimated that 60% of people with bipolar disorder also have a substance abuse problem.

Course of Bipolar Disorder

Onset of bipolar disorder usually occurs in the late teens or early 20’s. In a little greater than half of bipolar patients, the first episode is a depressive episode. At least 10% of those who experience a first lifetime event of major depression will eventually become bipolar, so it is important to monitor any patient with major depressive disorder for later onset of mania. Manic episodes begin with a rapid onset and can last weeks to months. Manic episodes occur in three stages:

• Stage I, or hypomania

Stage I is defined by heightened mood, grandiosity, pressured speech, a rapid flow of ideas, decreased concentration, increased distractability, hyperactivity, more energy and less need for sleep.

• Stage II, or acute mania

In Stage II all of the symptoms of Stage I are present and intensified, in addition, the patient experiences either delusions of grandeur or paranoia.

• Stage III, or delirious mania

In Stage III, all of the symptoms of Stage II are exacerbated, and the patient also presents with hallucinations, incoherence and bizarre behavior.

While all manic episodes display Stage I and a majority progress to Stage II, only some reach Stage III. Recovery from an episode of mania is usually thought to be around 4 months, with great variance.

Predictors of recovery include:

• Symptoms: Patients with "pure" mania seem to recover faster and more completely than patients with mixed or cycling symptoms.

• History of previous mood episodes (both depressive and manic episodes): In one long-term study (20 years), 85% of bipolar patients relapsed. The number of symptom free intervals tends to decrease over time (see below).

The predictors of relapse are not clear, however, some proposed predictors include:

• low vocational advancement at illness onset

• depression

• number of previous episodes

• mixed symptoms

• comorbidity (especially with alcoholism)

• psychotic features when manic

• interepisode features

Bipolar disorder cannot only be debilitating, but it can be deadly. Approximately 10 to 15 percent of Bipolar I patients complete suicide.

Treatment

Treatment for bipolar disorder is much more pharmacologically based than major depression. The treatment of acute mania and the prevention of future episodes may require different pharmacological approaches.

Lithium

Lithium was first used in 1949 by John Cade following lethargy production in guinea pigs. The mechanism of action is poorly understood, but probably at the level of the second messenger systems involving adenylate cyclase and phosphatidylinositol. Lithium has been shown to inhibit phosphatidylinositol creation and turnover, dampening this second messenger system, and possibly leading to mood stabilization. Lithium is a first line treatment for acute mania and is also used for long-term (prophylactic) bipolar treatment. Lithium may also prove useful for recurring unipolar depression. There is a narrow range between the therapeutic and toxic doses of lithium, so blood level monitoring for lithium toxicity is critical. Additionally, there is wide variability of lithium pharmacokinetics among different individuals; thus, optimum doses for an individual patient cannot be based on the dosage administered. While there is a 60% response rate overall, Lithium's efficacy is slow-- it works in about 7-14 days.

Side Effects of Lithium

At therapeutic doses, lithium can cause an inflammatory response in the kidney. Toxic doses, which are not too much higher than therapeutic doses, can damage kidney function. Nausea, vomiting, abdominal pain, diarrhea, tremor, coma, death are all associated with increasing toxicity. Diuretics and NSAIDS may increase lithium levels in the blood. Lithium use with antipsychotics may increase risk for neuroleptic malignant syndrome.

Anticonvulsants

Anti-epileptic drugs have shown some success in treating mania. Carbamazepine, which blocks the sodium channel opened by glutamate, slows the rate of neuronal recovery from the inactivated state. The mechanism of action of carbamazapine may relate to the process of "kindling,” an idea derived from seizures in which repetitive subthreshold electrical stimulation of the brain eventually may lead to either a behavioral or a convulsive response. In this model of affective illness, repeated biochemical or psychological stresses would result in abnormal limbic neuronal sensitization. Overall, efficacy of carbamazapine is 25-50%; it may be especially effective for dysphoric-type or mixed symptom mania.

Side Effects of Carbamazepine

The most common side effect is sedation; the most serious side effect is agranulocytosis. Patients should be warned of symptoms of bone marrow suppression (e.g., fever, sore throat, petechiae). Carbamazapine induces its own metabolism through induction of liver enzymes; thus, what is initially an effective dose may have to be increased later due to a drop in effective serum level following the induction of increased metabolism of the drug. Drug interactions are common with carbamazepine due to this same tendency to induce enzymes. Some drugs are metabolized faster in the presence of carbamazapine and many substances (such as erythromycin, ketoconazole and grapefruit juice) can raise carbamazepine levels, often drastically.

Though of interest, Carbamazepine is rarely used as a first line treatment for bipolar disorder, owing to its side effects. However, newer anticonvulsants are overtaking Lithium as a first line treatment for bipolar disorder. Among these, the strongest evidence is for the use of Valproic Acid, usually in the form of a sodium salt, (divalproex sodium) for the treatment of bipolar disorder. Valproate's mechanism of action is presumably similar to carbamazepine. Evidence of equal efficacy against mania for valproate and lithium has been shown in several studies, including a large placebo controlled study. Valproate may be particularly effective for bipolar patients who display rapid mood cycling.

Side Effects of Valproate

The most common side effect is sedation; the most dangerous side effect is hepatotoxicity. Valproate can cause neural tube defects (spina bifida, anencephaly) in pregnancy.

Other Anticonvulsants

Gabapentin has had several positive studies in bipolar patients, but they have generally been open studies will small populations. Gabapentin's mechanism of action is unknown. Its elimination half-life is 5 to 7 hours, and is primarily renally excreted. Gabapentin does not bind to plasma proteins and seems to be safe in overdose.

Lamotrigine is reported to possess moderate to marked efficacy in bipolar depression, hypomania, and mixed states; however, its efficacy in hospitalized mania is not clear.

This is on the basis of 14 clinical reports involving 207 patients with bipolar disorder (66 with rapid cycling). In practice, it is developing a reputation of being a preferred drug for bipolar depression: an entity considered hard to treat as standard antidepressants can be problematic in bipolar patients.

Newer anticonvulsants, such as topiramate and oxcarbazapine are promising for maintenance treatment of bipolar disorder, but more studies must be done. Oxcarbazapine is of interest as it is similar to Carbamazepine in structure.

Antipsychotics

Antipsychotics (formerly haloperidol, now more likely atypical antipsychotics such as olanzapine) have rapid effects and are also used to treat mania. Antidepressants appear to have both an acute effect on mania (which is likely a sedative effect), as well as a prophylactic effect. Thus antipsychotics can be used both as an acute intervention for a manic patient as well as a maintenance drug for bipolar disorder. Generally, typical antipsychotics such as haloperidol are only used only to treat acute mania, but the atypical antipsychotics are becoming more common in maintenance therapy, either alone or in combination with another mood stabilizer. Olanzapine is now generally considered a "first line" treatment for bipolar disorder.

Side Effects of Antipsychotics

Haloperidol has high extrapyramidal side effects and can cause tardive dyskinesia and neuroleptic malignant syndrome after long-term use. Olanzapine has anti-muscarinic effects such as sedation and dry mouth. While olanzapine long-term use can cause tardive dyskinesia and neuroleptic malignant syndrome, the risk is reportedly smaller with olanzapine versus haloperidol.

Sedatives

Sedatives such as Lorazepam (Ativan) and Clonazepam (Klonopin) may be as effective, and possibly faster and safer than antipsychotics for treatment of acute mania. Clonazepam is sometimes used also for maintenance, but is probably not as effective as other choices. Usually, high doses are used.

Antidepressants

Lithium, anti-psychotics and anticonvulsants can be effective to treat depressive episodes in bipolar patients, and these mood stabilizers should be used as the primary treatment. Antidepressants can be used if the mood stabilizers are not effective; however, there is the danger that antidepressants will induce mania in the bipolar patient. Therefore, if antidepressants are used with the bipolar patient, it is important to quickly taper down and discontinue their use once the depressive episode has been treated.

|Commonly used drugs for treating bipolar disorder |

|Class |T½ |Metabolism |Common Side Effects |Serious Side Effects |

|Lithium |24 hours |4-6 days |nausea, tremor, increased|CNS toxicity, renal |

| | | |urination and thirst. |toxicity |

|Valproate (Depakene, |5-13 hours |2-5 days |nausea, vomiting, |Thrombocytopenia, liver |

|Depakote) | | |drowsiness, tremor, |toxicity, pancreatitis |

| | | |dizziness. | |

|Carbamazepine (Tegretol) |12-17 hours |3-5 weeks |Drowsiness, dizziness, |Thrombocytopenia, |

| | | |ataxia, nausea. |neutropenia |

|Haldoperidol (Haldol) | | |Very high extrapyramidal |Tardive dyskinesia, |

| | | |side effects |neuroleptic malignant |

| | | | |syndrome |

|Olanzapine (Zyprexa) |21-54 hours |1-2 weeks |Sedation, dry mouth. |Tardive dyskinesia, |

| | | | |neuroleptic malignant |

| | | | |syndrome (but risk is |

| | | | |lower than with |

| | | | |haloperidol) |

|Benzodiazepines (Lorazepam,|Short for lorazepam, | |Sedation, dizziness, |Tolerance, withdrawal |

|Clonazepam) |longer for clonazepam | |weakness, ataxia, |(with long term usage), |

| | | |decreased motoric |addiction, paradoxical |

| | | |performance |excitement |

-----------------------

| |Depression |

|General |Signs of poor self |

| |care, soft, slow |

| |speech, psychomotor |

| |retardation |

|Emotional |Mood |Dysphoric, angry or |

| | |apathetic |

| |Affect |Blunted, sad, |

| | |constricted |

|Thought |Process |Slowed process, though |

| | |blocking |

| |Content |Guilty, |

| | |self-deprecating, |

| | |suicidal ideation |

|Cognition |Poor attention, |

| |concentration, |

| |registration, poor |

| |effort |

Major depressive episode

1. Depressive symptoms represent a change from previous functioning

2. Symptoms must occur for at least 2 weeks

3. Symptom list (5 or more, 1 has to be depressed mood or anhedonia)

-mnemonic: "SIG E CAPS":

• Sleep

• Interest

• Guilt

• Energy

• Concentration

• Appetite

• Psychomotor Retardation

• Suicidal ideation

4. The Global Criteria (i.e. must “cause clinically significant distress or impairment in social, occupational or other important areas of functioning”)

Major depressive disorder

Conceptually: this is the "classical" depressive diagnosis and requires the presence of a Major Depressive Episode (see above).

Specifiers for Major Depression:

• Level of Severity

• Course Specifiers

• Special types:

o Catatonic

o Melancholic

o Atypical

o Postpartum

• Rule out:

o some other psychiatric disorder

o history of manic, mixed or hypomanic episode

•

Mixed Anxiety-Depression: Observations of the common overlap between anxiety and depressive symptoms lead to the addition of this category to the DSM-IV. The presence of this common syndrome may predict a poorer course of illness.

Self-medication: Perhaps alcoholics are "medicating" their mood disorder. There is little data to support this theory and it is mostly based on clinical observation.

Forme frustre: Perhaps alcoholism is part of a depressive spectrum of disorders. Twin studies suggest that the substantial comorbidity between major depression and alcoholism results primarily from genetic factors influencing the risk to both disorders. This does not mean, however, that major depression and alcoholism are manifestations of the same disorder. The two disorders appear to have both common and separate genetic factors that independently influence the susceptibility to either disorder.

Secondary mood disorders: Perhaps alcohol causes depression. The strongest support exists for this theory. Investigators at a NYC VA Hospital withdrew depressed alcoholics, and observed depressive symptoms improve over the next 4 weeks without specific treatment of depression.

Other Psychiatric Disorders where depression is common:

• Somatoform Disorders: particularly hypochondria and somatization disorder.

• Eating Disorders: particularly anorexia nervosa.

• Attention Deficit Disorders: perhaps a third of children with ADD will also have a mood disorder (usually major depression).

Medical Outcomes Study (Wells et al.,1989)

Studied more than 22,000 patients receiving care from 523 clinicians. Focused on five specific diseases: myocardial infarction, congestive heart failure, hypertension, diabetes and depression.

An additive effect on patient's functioning was observed between depression and other chronic medical illnesses, suggesting a worse course for the medically co-morbid depressed patients.

In a 2-year follow-up, they found that certain medical disorders predicted a worse course of depression, whereas others did not. The most adverse association was between myocardial infarction and depression: depressed patients with a history of myocardial infarction had more frequent spells and worse symptoms of depression during the period of follow-up.

The Collaborative Depression Study (CDS), a multi-center naturalistic study of the course of depression.

• 54% of the patients recovered within the first six months of the study.

• Approximately 70% recovered within one year.

• 81% were recovered after two years, 87% after 4 years and 88% after five.

• Thus, many of the patients who were still depressed after one years had not recovered by year five.

• In the CDS study, 22% of recovered patients relapsed within 1 year. Relapse was quicker if the patient had a history of recurrent episodes.

Serotonin Syndrome.

Combining several serotonin enhancing drugs can cause serotonin syndrome, characterized by euphoria, drowsiness, sustained rapid eye movement, overreaction of the reflexes, rapid muscle contraction and relaxation in the ankle causing abnormal movements of the foot, clumsiness, restlessness, feeling drunk and dizzy, muscle contraction and relaxation in the jaw, sweating, intoxication, muscle twitching, rigidity, high body temperature, mental status changes were frequent (including confusion and hypomania - a "happy drunk" state), shivering, diarrhea, loss of consciousness and death.

| |Mania |

|General |Flamboyant appearance, |

| |rapid, pressured |

| |speech, agitation or |

| |increased movement |

|Emotional |Mood |Euphoric, irritable |

| |Affect |Heightened, dramatic, |

| | |labile |

|Thought |Process |Flight of ideas, loose |

| | |associations |

| |Content |Grandiosity, delusions |

|Cognition |Distractible, poor |

| |concentration |

Manic Episode

1. Symptoms must occur for 1 week (any duration if hospitalization is necessary)

2. Symptom list (3 or more--four if the mood is only irritable):

• grandiosity

• decreased need for sleep

• pressured speech

• flight of ideas

• increased distractibility

• increased activity/agitation

• increased engagement in risky activities

3. The Global Criteria (i.e. “sufficiently severe to cause marked impairment in occupational functioning or in usual social activities or relationships with others or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features”)

Hypomanic Episode

Basically the same as Manic Episode, except:

1. Symptoms can last only 4 days

!%-FŠ’Æ Ø

?#

=

>

@

N

Z

‚

æ

ë

-

2J[˜¡"35UWhj„†¨ã- ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download